Semaglutide's other names — Wegovy, Ozempic and Rybelsus explained

The misconception: 'It's all the same drug, so any version will do'

This is the most common misunderstanding about semaglutide, and it's worth correcting head-on. Yes, Wegovy, Ozempic and Rybelsus all contain semaglutide. But UK medicines law ties each brand to a specific licensed indication, and a prescriber cannot legally offer a diabetes medicine as a weight-loss treatment simply because the molecule is the same. The NHS semaglutide medicines page sets this out clearly: Wegovy is the weight-management brand; Ozempic is for type 2 diabetes. Treating them as interchangeable isn't a shortcut, it's a clinical and legal error.

It also matters practically. The doses differ significantly. Ozempic tops out at 2mg for diabetes management. Wegovy's injection titrates to 2.4mg (and now a 7.2mg dose is also available following MHRA approval in early 2026) for weight management. Those are not the same dose, delivered for the same purpose, under the same supervision.

If you've seen semaglutide described on forums or social media without a brand name attached, that's another prompt to check the source carefully. Sellers offering semaglutide for weight loss without a prescription from a regulated pharmacy sit outside the licensed supply chain entirely.

The weight-loss names: Wegovy injection and Wegovy tablets

For weight management specifically, there are now two licensed semaglutide products in the UK. The Wegovy injection is a once-weekly subcutaneous pen, titrated from 0.25mg up to 2.4mg (or 7.2mg at the higher dose approved in 2026), licensed for adults with a BMI of 30 or above, or from 27 with a weight-related health condition alongside it.

Then, from 11 June 2026, the MHRA approved Wegovy tablets, the first oral GLP-1 weight-management medicine to be licensed in the UK. The tablet form contains the same semaglutide but is co-formulated with an absorption enhancer called SNAC so it can work when swallowed rather than injected. Dosing starts at 1.5mg daily, escalating through 4mg and 9mg to a 25mg maintenance dose. No refrigeration needed, which makes it meaningfully more convenient for some people. Both forms of semaglutide for weight loss are prescription-only, and the clinical eligibility criteria are similar across injection and tablet.

A quick check worth doing: if you're looking at any online source that claims to sell Wegovy, pull up the GPhC pharmacy register at pharmacyregulation.org/registers and search the pharmacy's name. It takes under a minute, and if they're not listed, stop there.

The diabetes names: Ozempic and Rybelsus

Ozempic is a once-weekly semaglutide injection licensed for type 2 diabetes in the UK. It became widely known during the weight-loss medicine shortage partly because people with diabetes were losing weight on it, but weight loss is a side effect of the diabetes licence, not the licensed purpose. Prescribing Ozempic specifically to manage weight, rather than blood glucose, would fall outside its UK authorisation. The MHRA has been clear on this.

Rybelsus is oral semaglutide, also for type 2 diabetes, at 3mg, 7mg and 14mg. It predates Wegovy tablets by some years and is easily confused with them, but the doses are different and so is the licence. The background on semaglutide as a drug class explains the distinction in more detail. Rybelsus strengths should never be read as steps in the Wegovy weight-loss tablet schedule, the two products are entirely separate.

The takeaway: if someone tells you Ozempic or Rybelsus is 'basically the same as Wegovy for weight loss,' they're describing the molecule correctly but ignoring the licence, the dose and the legal framework around prescribing. Those details exist for clinical reasons, not bureaucratic ones. You can explore how the Wegovy brand name emerged from the same clinical development programme if you'd like the fuller history.

Does the brand name affect how well it works?

The active ingredient is identical across all semaglutide brands, GLP-1 receptor agonist, same mechanism, same core pharmacology. What differs is dose, delivery format and licensed purpose. Within the weight-management indication, the clinical trial evidence (STEP 1, published in the New England Journal of Medicine) showed around 15% average weight reduction over 68 weeks at the 2.4mg injectable dose alongside lifestyle changes. The newer 7.2mg injectable dose trials reported approximately 20.7% over 72 weeks. The Wegovy tablet's phase 3 trial reported around 13.6% average weight loss over 64 weeks among participants with obesity or overweight and at least one weight-related condition.

None of those figures come from Ozempic or Rybelsus trials at diabetes doses, the datasets are genuinely separate. For weight management, only the Wegovy-licensed products and their corresponding trial evidence apply. A prescriber working through your consultation will consider which form suits your circumstances. Side effects share the same general profile across the semaglutide family: the most commonly reported are gastrointestinal (nausea, loose stools, constipation, reflux) typically settling as the body adjusts to treatment, though it's worth reading the full side-effect picture before starting.

If you're thinking about weight management with semaglutide and want to understand your options properly, speaking to a prescriber is the right next step. Our prescribers at nume's clinical team review every consultation personally (not by automated decision) the same day it's submitted. You can start a free consultation to find out whether treatment is suitable for you.